175 related articles for article (PubMed ID: 37116711)
1. Tripartite motif 38 alleviates the pathological process of NAFLD-NASH by promoting TAB2 degradation.
Yao X; Dong R; Hu S; Liu Z; Cui J; Hu F; Cheng X; Wang X; Ma T; Tian S; Zhang XJ; Hu Y; Bai L; Li H; Zhang P
J Lipid Res; 2023 Jul; 64(7):100382. PubMed ID: 37116711
[TBL] [Abstract][Full Text] [Related]
2. Targeting DUSP7 signaling alleviates hepatic steatosis, inflammation and oxidative stress in high fat diet (HFD)-fed mice via suppression of TAK1.
Wu L; Liu Y; Zhao Y; Li M; Guo L
Free Radic Biol Med; 2020 Jun; 153():140-158. PubMed ID: 32311490
[TBL] [Abstract][Full Text] [Related]
3. Dual-Specificity Phosphatase 26 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through Transforming Growth Factor Beta-Activated Kinase 1 Suppression.
Ye P; Liu J; Xu W; Liu D; Ding X; Le S; Zhang H; Chen S; Chen M; Xia J
Hepatology; 2019 May; 69(5):1946-1964. PubMed ID: 30582764
[TBL] [Abstract][Full Text] [Related]
4. TRIM38 inhibits TNFα- and IL-1β-triggered NF-κB activation by mediating lysosome-dependent degradation of TAB2/3.
Hu MM; Yang Q; Zhang J; Liu SM; Zhang Y; Lin H; Huang ZF; Wang YY; Zhang XD; Zhong B; Shu HB
Proc Natl Acad Sci U S A; 2014 Jan; 111(4):1509-14. PubMed ID: 24434549
[TBL] [Abstract][Full Text] [Related]
5. The role of hepassocin in the development of non-alcoholic fatty liver disease.
Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
[TBL] [Abstract][Full Text] [Related]
6. Tripartite motif 16 ameliorates nonalcoholic steatohepatitis by promoting the degradation of phospho-TAK1.
Wang L; Zhang X; Lin ZB; Yang PJ; Xu H; Duan JL; Ruan B; Song P; Liu JJ; Yue ZS; Fang ZQ; Hu H; Liu Z; Huang XL; Yang L; Tian S; Tao KS; Han H; Dou KF
Cell Metab; 2021 Jul; 33(7):1372-1388.e7. PubMed ID: 34146477
[TBL] [Abstract][Full Text] [Related]
7. Tripartite motif 38 attenuates cardiac fibrosis after myocardial infarction by suppressing TAK1 activation via TAB2/3 degradation.
Lu Z; Hao C; Qian H; Zhao Y; Bo X; Yao Y; Ma G; Chen L
iScience; 2022 Aug; 25(8):104780. PubMed ID: 35982795
[TBL] [Abstract][Full Text] [Related]
8. Deletion of Smurf1 attenuates liver steatosis via stabilization of p53.
Lin W; Zhang X; Zhang C; Li L; Zhang J; Xie P; Zhan Y; An W
Lab Invest; 2022 Oct; 102(10):1075-1087. PubMed ID: 35672379
[TBL] [Abstract][Full Text] [Related]
9. Asperuloside alleviates lipid accumulation and inflammation in HFD-induced NAFLD via AMPK signaling pathway and NLRP3 inflammasome.
Shen Q; Chen Y; Shi J; Pei C; Chen S; Huang S; Li W; Shi X; Liang J; Hou S
Eur J Pharmacol; 2023 Mar; 942():175504. PubMed ID: 36641101
[TBL] [Abstract][Full Text] [Related]
10. p16 INK4A drives nonalcoholic fatty liver disease phenotypes in high fat diet fed mice through biliary E2F1/FOXO1/IGF-1 signaling.
Kundu D; Kennedy L; Zhou T; Ekser B; Meadows V; Sybenga A; Kyritsi K; Chen L; Ceci L; Wu N; Wu C; Glaser S; Carpino G; Onori P; Gaudio E; Alpini G; Francis H
Hepatology; 2023 Jul; 78(1):243-257. PubMed ID: 36799449
[TBL] [Abstract][Full Text] [Related]
11. Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function.
Zhang J; Zhang W; Yang L; Zhao W; Liu Z; Wang E; Wang J
Phytomedicine; 2023 Jan; 109():154589. PubMed ID: 36610145
[TBL] [Abstract][Full Text] [Related]
12. RNA helicase DEAD-box protein 5 alleviates nonalcoholic steatohepatitis progression via tethering TSC complex and suppressing mTORC1 signaling.
Zhang Y; Ye S; Lu W; Zhong J; Leng Y; Yang T; Luo J; Xu W; Zhang H; Kong L
Hepatology; 2023 May; 77(5):1670-1687. PubMed ID: 35796622
[TBL] [Abstract][Full Text] [Related]
13. Tripartite motif-containing protein 38 negatively regulates TLR3/4- and RIG-I-mediated IFN-β production and antiviral response by targeting NAP1.
Zhao W; Wang L; Zhang M; Wang P; Yuan C; Qi J; Meng H; Gao C
J Immunol; 2012 Jun; 188(11):5311-8. PubMed ID: 22539786
[TBL] [Abstract][Full Text] [Related]
14. Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway.
Wu YK; Ren ZN; Zhu SL; Wu YZ; Wang G; Zhang H; Chen W; He Z; Ye XL; Zhai QX
Acta Pharmacol Sin; 2022 Jun; 43(6):1473-1483. PubMed ID: 34654875
[TBL] [Abstract][Full Text] [Related]
15. SIRT2 Deficiency Aggravates Diet-Induced Nonalcoholic Fatty Liver Disease through Modulating Gut Microbiota and Metabolites.
Li X; Du Y; Xue C; Kang X; Sun C; Peng H; Fang L; Han Y; Xu X; Zhao C
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240315
[TBL] [Abstract][Full Text] [Related]
16. iRhom2 Promotes Hepatic Steatosis by Activating MAP3K7-Dependent Pathway.
Xu M; Ge C; Zhu L; Qin Y; Du C; Lou D; Li Q; Hu L; Sun Y; Dai X; Xiong M; Long T; Zhan J; Kuang Q; Li H; Yang Q; Huang P; Teng X; Feng J; Wu Y; Dong W; Wang B; Tan J
Hepatology; 2021 Apr; 73(4):1346-1364. PubMed ID: 32592194
[TBL] [Abstract][Full Text] [Related]
17. Fatty Acid Synthase-Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD.
Hu Y; He W; Huang Y; Xiang H; Guo J; Che Y; Cheng X; Hu F; Hu M; Ma T; Yu J; Tian H; Tian S; Ji YX; Zhang P; She ZG; Zhang XJ; Huang Z; Yang J; Li H
Hepatology; 2021 Nov; 74(5):2508-2525. PubMed ID: 34231239
[TBL] [Abstract][Full Text] [Related]
18. Human germline hedgehog pathway mutations predispose to fatty liver.
Guillen-Sacoto MJ; Martinez AF; Abe Y; Kruszka P; Weiss K; Everson JL; Bataller R; Kleiner DE; Ward JM; Sulik KK; Lipinski RJ; Solomon BD; Muenke M
J Hepatol; 2017 Oct; 67(4):809-817. PubMed ID: 28645738
[TBL] [Abstract][Full Text] [Related]
19. Adzuki bean ameliorates hepatic lipogenesis and proinflammatory mediator expression in mice fed a high-cholesterol and high-fat diet to induce nonalcoholic fatty liver disease.
Kim S; Hong J; Jeon R; Kim HS
Nutr Res; 2016 Jan; 36(1):90-100. PubMed ID: 26773785
[TBL] [Abstract][Full Text] [Related]
20. PREX1 depletion ameliorates high-fat diet-induced non-alcoholic fatty liver disease in mice and mitigates palmitic acid-induced hepatocellular injury via suppressing the NF-κB signaling pathway.
Li Z; Wu K; Zou Y; Gong W; Wang P; Wang H
Toxicol Appl Pharmacol; 2022 Aug; 448():116074. PubMed ID: 35605788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
